Research programme: autoimmune and inflammatory disorders therapeutics - FF Pharmaceuticals

Drug Profile

Research programme: autoimmune and inflammatory disorders therapeutics - FF Pharmaceuticals

Alternative Names: FFP 106; PG 120; PG 140

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator PanGenetics BV
  • Developer FF Pharma; PanGenetics BV
  • Class Antibodies; Monoclonal antibodies
  • Mechanism of Action CD40 antigen inhibitors; CD86 antigen inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Digestive system disorders; Transplant rejection
  • No development reported Autoimmune disorders; Inflammation
  • Discontinued Cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Autoimmune-disorders in Netherlands
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammation in Netherlands (IV)
  • 11 Jul 2014 FF Pharmaceuticals plans a phase I/II trial for Primary biliary cirrhosis in the Netherlands (NCT02193360)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top